Evidence map›Paper›PMID 25897797›Full record

Trial reportBMC psychiatry2015

Primary prevention of psychosis through interventions in the symptomatic prodromal phase, a pragmatic Norwegian Ultra High Risk study.

Inge Joa, Jens Gisselgård, Kolbjørn Brønnick, Thomas McGlashan, Jan Olav Johannessen

Open access · goldAbstract readPragmatic Clinical Trial
In one paragraph

Trial report in BMC psychiatry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 2 pooled it
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Interventions for prodromal stage of psychosis.The Cochrane database of systematic reviews · 2019
    Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. mHealth · 2020
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Understanding the schizophrenia prodrome.Indian journal of psychiatry
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Inge JoaPsychiatric Division, Stavanger University Hospital, TIPS- Centre for Clinical Research in Psychosis, Armauer Hansensvei 20, N-4011, Stavanger, Norway. inge.joa@sus.no.
Jens GisselgårdPsychiatric Division, Stavanger University Hospital, TIPS- Centre for Clinical Research in Psychosis, Armauer Hansensvei 20, N-4011, Stavanger, Norway. jens.petter.gisselgard@sus.no.
Kolbjørn BrønnickPsychiatric Division, Stavanger University Hospital, TIPS- Centre for Clinical Research in Psychosis, Armauer Hansensvei 20, N-4011, Stavanger, Norway. kolbjorn.selvag.bronnick@sus.no.
Thomas McGlashanDepartment of Psychiatry, Yale University, New Haven, CT, USA. thomas.mcglashan@yale.edu.
Jan Olav JohannessenPsychiatric Division, Stavanger University Hospital, TIPS- Centre for Clinical Research in Psychosis, Armauer Hansensvei 20, N-4011, Stavanger, Norway. jojo@sus.no.
Stavanger University Hospital · NOUniversity of Stavanger · NOYale University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEvidence has been accumulating that it may be possible to achieve prevention in psychotic disorders. The aim of the Prevention Of Psychosis (POP) study is to reduce the annual incidence of psychotic disorders in a catchment area population through detection and intervention in the prodromal phase of disorder. Prodromal patients will be recruited through information campaigns modelled on the Scandinavian early Treatment and Intervention in Psychosis (TIPS) study and assessed by low-threshold detection teams. METHODS/

designThe study will use a parallel control design comparing the incidence of first episode psychotic disorders between two Norwegian catchment areas with prodromal detection and treatment (Stavanger and Fonna) with two catchment areas without a prodromal intervention program (Bergen and Østfold). The primary aim of the current study is to test the effect of a Prodromal Detection and Treatment program at the health care systems level. The study will investigate: 1) If the combination of information campaigns and detection teams modelled will help in identifying individuals (age 13-65, fulfilling study inclusion criteria) at high risk of developing psychosis early, and 2) If a graded, multi-modal treatment program will reduce rates of conversion compared to the rates seen in follow-along assessments. DISCUSSION: Positive results could potentially revolutionize therapy by treating risk earlier rather than disorder later and could open a new era of early detection and intervention in psychosis. Negative results will suggest that the potential for psychosis is determined early in life and that research should focus more on genetically linked neurodevelopmental processes. If we can identify people about to become psychotic with high accuracy, we can track them to understand more about how psychosis unfolds. Appropriate intervention at this stage could also prevent or delay the onset of psychosis and/or subsequent deterioration, i.e., social and instrumental disability, suicide, aggressive behavior, affective- and cognitive deficits.

trial registrationCurrent Controlled Trials ISRCTN20328848 . Registered 02 November 2014.

Indexed as

Prodromal SymptomsPsychotherapyAdolescentAdultAgedBrainClinical ProtocolsCombined Modality TherapyEarly DiagnosisFatty Acids, Omega-3FemaleFunctional NeuroimagingHumansMagnetic Resonance ImagingMaleMiddle AgedFatty Acids, Omega-3

Identifiers

PMID25897797
PMCPMC4422504
OpenAlexW2047428488

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.